Abstract |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.
|
Authors | Marie Dubert, Benoit Visseaux, Valentina Isernia, Lila Bouadma, Laurène Deconinck, Juliette Patrier, Paul-Henri Wicky, Diane Le Pluart, Laura Kramer, Christophe Rioux, Quentin Le Hingrat, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Jade Ghosn, Francois-Xavier Lescure |
Journal | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
(Int J Infect Dis)
Vol. 98
Pg. 290-293
(Sep 2020)
ISSN: 1878-3511 [Electronic] Canada |
PMID | 32619764
(Publication Type: Case Reports)
|
Copyright | Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- Antiviral Agents
- remdesivir
- Adenosine Monophosphate
- Alanine
|
Topics |
- Adenosine Monophosphate
(adverse effects, analogs & derivatives, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Alanine
(adverse effects, analogs & derivatives, therapeutic use)
- Antiviral Agents
(adverse effects, therapeutic use)
- Betacoronavirus
(drug effects, physiology)
- COVID-19
- Coronavirus Infections
(drug therapy, virology)
- Female
- France
- Hospitalization
- Humans
- Male
- Pandemics
- Pneumonia, Viral
(drug therapy, virology)
- SARS-CoV-2
- Viral Load
(drug effects)
- Withholding Treatment
|